ENDRA Life Sciences (NASDAQ:NDRA) Shares Up 6.5% – Here’s What Happened

ENDRA Life Sciences Inc. (NASDAQ:NDRA) shot up 6.5% during mid-day trading on Friday . The company traded as high as $6.37 and last traded at $6.05. 20,582 shares were traded during mid-day trading, a decline of 50% from the average session volume of 41,006 shares. The stock had previously closed at $5.68.

Analysts Set New Price Targets

Several research firms have commented on NDRA. Ascendiant Capital Markets cut their price target on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Weiss Ratings downgraded ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, ENDRA Life Sciences currently has an average rating of “Hold” and an average price target of $25.00.

ENDRA Life Sciences Price Performance

The business’s 50 day simple moving average is $4.93 and its 200 day simple moving average is $4.72. The company has a market capitalization of $9.07 million, a price-to-earnings ratio of -0.95 and a beta of -0.05.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its earnings results on Friday, August 14th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.21. As a group, analysts expect that ENDRA Life Sciences Inc. will post -4.11 EPS for the current fiscal year.

Institutional Trading of ENDRA Life Sciences

An institutional investor recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th biggest position. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. 1.19% of the stock is owned by hedge funds and other institutional investors.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.